Maxim lowered the firm's price target on NexGel to $2 from $6 and keeps a Buy rating on the shares. The company's Celularity acquisition could be transformative for NexGel and turn it into a profitable entity, however the firm is adjusting its price target to reflect the dilution related to the financing for the deal, the analyst tells investors in a research note.
